PMID- 35861930
OWN - NLM
STAT- MEDLINE
DCOM- 20221018
LR  - 20221019
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 41
IP  - 11
DP  - 2022 Nov
TI  - Serum interleukin-23 levels: relation to depression, anxiety, and disease 
      activity in psoriatic arthritis patients.
PG  - 3391-3399
LID - 10.1007/s10067-022-06300-1 [doi]
AB  - OBJECTIVES: Assessment of serum levels of IL-23 in PsA patients and its 
      correlation with depression, anxiety, and disease activity. METHODS: Eighty 
      psoriatic arthritis (PsA) patients and eighty healthy volunteers matched for age 
      and gender were included in this observational case-control study. All 
      participants suspected to detailed history, clinical assessment, PsA activity 
      using Disease Activity Index for Psoriatic Arthritis (DAPSA) score, the severity 
      and extent of psoriasis was assessed by the Psoriasis Area and Severity Index 
      (PASI), and ultrasonographic assessments of the entheses were examined according 
      to the Madrid Sonographic Enthesitis Index (MASEI). Depression and anxiety were 
      assessed by Hospital Anxiety and Depression Scale (HADS). Serum IL-23 was 
      measured and correlated with disease activity, depression, and anxiety. RESULTS: 
      There was no significant difference between patients and controls regarding 
      demographic data. Thirty-six PsA patients (45%) had anxiety and 28 patients (35%) 
      had depression, while in the control group, 16 persons (20%) had anxiety and 12 
      (15%) had depression, with significant differences between the 2 groups 
      (p < 0.0001). There were significant differences in HADS anxiety and depression 
      scores between patients and controls with significant positive correlations 
      between HADS depression, anxiety scores and IL-23, DAPSA, PASI, and MASEI scores 
      (p < 0.05). IL-23 was positively correlated with DAPSA, PASI, and HADS scores; we 
      observed that interleukin 23, higher DAPSA, and PASI were independently 
      associated with depression and anxiety. CONCLUSION: Serum interleukin-23 levels 
      were elevated in PsA patients and were found to be correlated with depression, 
      anxiety, and disease activity. Key Points * Psoriatic arthritis is a 
      multidimensional disorder with psychiatric drawbacks. * Interleukin-23 is a 
      proinflammatory cytokines that was correlated with depression and anxiety in PsA 
      patients. * Interleukin-23 was correlated with disease activity in PsA. * 
      Depression and anxiety were positively correlated with disease activity in PsA.
CI  - (c) 2022. The Author(s).
FAU - Tabra, Samar Abdalhamed
AU  - Tabra SA
AUID- ORCID: 0000-0001-6414-5602
AD  - Department of Rheumatology and Rehabilitation, Faculty of Medicine, Tanta 
      University, Tanta, Egypt.
FAU - Abd Elghany, Salwa Elmorsy
AU  - Abd Elghany SE
AUID- ORCID: 0000-0002-0901-8800
AD  - Department of Rheumatology and Rehabilitation, Faculty of Medicine, Tanta 
      University, Tanta, Egypt.
FAU - Amer, Reham A
AU  - Amer RA
AD  - Department of Neuropsychiatry, Faculty of Medicine, Tanta University, Tanta, 
      Egypt.
FAU - Fouda, Mohamed H
AU  - Fouda MH
AD  - Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, 
      Egypt.
FAU - Abu-Zaid, Mohammed Hassan
AU  - Abu-Zaid MH
AUID- ORCID: 0000-0001-8436-8598
AD  - Department of Rheumatology and Rehabilitation, Faculty of Medicine, Tanta 
      University, Tanta, Egypt. drmhassan113@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220721
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Interleukin-23)
SB  - IM
MH  - Anxiety
MH  - *Arthritis, Psoriatic/complications
MH  - Case-Control Studies
MH  - Depression
MH  - Humans
MH  - Interleukin-23
MH  - *Psoriasis
MH  - Severity of Illness Index
PMC - PMC9301620
OTO - NOTNLM
OT  - Anxiety
OT  - Depression
OT  - Disease activity
OT  - HADS score
OT  - IL-23
OT  - Psoriatic arthritis
EDAT- 2022/07/22 06:00
MHDA- 2022/10/19 06:00
PMCR- 2022/07/21
CRDT- 2022/07/21 11:20
PHST- 2022/03/09 00:00 [received]
PHST- 2022/07/12 00:00 [accepted]
PHST- 2022/07/11 00:00 [revised]
PHST- 2022/07/22 06:00 [pubmed]
PHST- 2022/10/19 06:00 [medline]
PHST- 2022/07/21 11:20 [entrez]
PHST- 2022/07/21 00:00 [pmc-release]
AID - 10.1007/s10067-022-06300-1 [pii]
AID - 6300 [pii]
AID - 10.1007/s10067-022-06300-1 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2022 Nov;41(11):3391-3399. doi: 10.1007/s10067-022-06300-1. Epub 
      2022 Jul 21.